Literature DB >> 8421803

Limiting the anatomic extent of upper thoracic sympathectomy for primary palmar hyperhidrosis.

D S O'Riordain1, M Maher, D J Waldron, B O'Donovan, M P Brady.   

Abstract

Ninety-four consecutive patients undergoing bilateral sympathectomy of the upper part of the thorax for primary palmar hyperhidrosis were reviewed. The supraclavicular operative approach was used and a limited sympathectomy was performed from below T1 to above T3, denervating the palm only. Follow-up evaluation was complete in 86 patients at a median period of 31 months. All patients had complete and permanent relief of palmar hyperhidrosis. However, 19 had compensatory hyperhidrosis and this was the common cause of patient dissatisfaction. Although axillary denervation was not performed, axillary sweating was a problem postoperatively in only two patients. Significant morbidity was minimal; the only permanent disability was in one patient with Horner's syndrome. Upper thoracic sympathectomy is a safe and effective method of treatment for primary palmar hyperhidrosis. The low incidence of compensatory sweating may be explained by the limited extent of the sympathectomy. Axillary sweating is rarely a significant postoperative problem, and extensive sympathectomy to include axillary denervation is unnecessary and should be avoided to minimize compensatory hyperhidrosis.

Entities:  

Mesh:

Year:  1993        PMID: 8421803

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  9 in total

1.  The body mass index and level of resection: predictive factors for compensatory sweating after sympathectomy.

Authors:  José Ribas Milanez de Campos; Nelson Wolosker; Flavio Roberto Takeda; Paulo Kauffman; Sergio Kuzniec; Fábio Biscegli Jatene; Sérgio Almeida de Oliveira
Journal:  Clin Auton Res       Date:  2005-04       Impact factor: 4.435

2.  Endoscopic transthoracic limited sympathotomy for palmar-plantar hyperhidrosis: outcomes and complications during a 10-year period.

Authors:  John L D Atkinson; Nicolee C Fode-Thomas; Robert D Fealey; John H Eisenach; Stephan J Goerss
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

3.  The long-term results of upper dorsal sympathetic ganglionectomy and endoscopic thoracic sympathectomy for palmar hyperhidrosis.

Authors:  C L Lin; C P Yen; S L Howng
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 4.  The treatment of primary palmar hyperhidrosis: a review.

Authors:  M Hashmonai; D Kopelman; A Assalia
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

5.  Is gender a predictive factor for satisfaction among patients undergoing sympathectomy to treat palmar hyperhidrosis?

Authors:  Nelson Wolosker; Marco Antonio Soares Munia; Paulo Kauffman; José Ribas Milanez de Campos; Guilherme Yazbek; Pedro Puech-Leão
Journal:  Clinics (Sao Paulo)       Date:  2010-06       Impact factor: 2.365

6.  Thoracoscopic sympathectomy for palmar and axillary hyperhidrosis: four-year outcome and quality of life after bilateral 5-mm dual port approach.

Authors:  Kai Bachmann; Nicola Standl; Jussuf Kaifi; Phillip Busch; Eva Winkler; Oliver Mann; Jakob R Izbicki; Tim Strate
Journal:  Surg Endosc       Date:  2009-03-04       Impact factor: 4.584

7.  Surgical treatment of facial blushing: Patient selection and operative technique (retrospective observational study).

Authors:  Jae Kil Park; Kwanyong Hyun; Mi Hyoung Moon; Jungsun Lee
Journal:  Medicine (Baltimore)       Date:  2022-07-08       Impact factor: 1.817

8.  Twenty months of evolution following sympathectomy on patients with palmar hyperhidrosis: sympathectomy at the T3 level is better than at the T2 level.

Authors:  Guilherme Yazbek; Nelson Wolosker; Paulo Kauffman; José Ribas Milanez de Campos; Pedro Puech-Leão; Fábio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

9.  Surgical treatment of compensatory hyperhidrosis: Retrospective observational study.

Authors:  Mi Hyoung Moon; Kwanyong Hyun; Jae Kil Park; Jungsun Lee
Journal:  Medicine (Baltimore)       Date:  2020-10-16       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.